Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 308 entries
View as:

Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00942799 Org: User:
Start: 07/31/09 End: 01/31/13 Due: 01/31/14

Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00125827 Org: User:
Start: 10/31/03 End: 02/28/06 Due: 02/28/07

A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

Phase: N/A Priority: Normal
NCT ID: NCT00295763 Org: User:
Start: 05/31/06 End: 09/30/06 Due: 09/30/07

Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02221492 Org: User:
Start: 11/30/14 End: 03/31/16 Due: 03/31/17

A Study to Assess Any Potential Interaction Between Colesevelam and Ciclosporin in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00692250 Org: User:
Start: 09/30/07 End: 12/31/07 Due: 12/31/08

Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee

Phase: N/A Priority: Normal
NCT ID: NCT02845271 Org: User:
Start: 07/21/16 End: 09/13/17 Due: 09/13/18

A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).

Phase: N/A Priority: Normal
NCT ID: NCT00838357 Org: User:
Start: 09/30/08 End: 11/30/10 Due: 11/30/11

A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent

Phase: N/A Priority: Normal
NCT ID: NCT01579149 Org: User:
Start: 09/30/11 End: 02/29/12 Due: 02/28/13

Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia

Phase: N/A Priority: Normal
NCT ID: NCT01857024 Org: User:
Start: 09/30/10 End: 10/31/12 Due: 10/31/13

A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)

Phase: N/A Priority: Normal
NCT ID: NCT00991133 Org: User:
Start: 10/31/09 End: 04/30/11 Due: 04/30/12

Study of the Effects of Fabrazyme Treatment on Lactation and Infants

Phase: N/A Priority: Normal
NCT ID: NCT00230607 Org: User:
Start: 05/28/06 End: 02/09/24 Due: 02/09/25

An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease

Phase: N/A Priority: Normal
NCT ID: NCT01574326 Org: User:
Start: 05/31/12 End: 06/30/15 Due: 06/30/16

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)

Phase: N/A Priority: Normal
NCT ID: NCT00891202 Org: User:
Start: 11/30/09 End: 01/31/16 Due: 01/31/17

A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours

Phase: N/A Priority: Normal
NCT ID: NCT01736163 Org: User:
Start: 05/31/12 End: 08/31/12 Due: 08/31/13

Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT00322387 Org: User:
Start: 04/30/04 End: 07/31/06 Due: 07/31/07

Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease

Phase: N/A Priority: Normal
NCT ID: NCT02489344 Org: User:
Start: 07/07/15 End: 11/20/18 Due: 11/20/19

Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis

Phase: N/A Priority: Normal
NCT ID: NCT00268957 Org: User:
Start: 01/31/06 End: 05/31/07 Due: 05/31/08

A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT02004704 Org: User:
Start: 12/04/13 End: 09/06/23 Due: 09/06/24

A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT01357811 Org: User:
Start: 08/31/11 End: 11/30/11 Due: 11/30/12

Growth and Development Study of Alglucosidase Alfa

Phase: N/A Priority: Normal
NCT ID: NCT00486889 Org: User:
Start: 08/26/08 End: 11/23/21 Due: 11/23/22

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00364351 Org: User:
Start: 08/31/06 End: 11/30/16 Due: 11/30/17

Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication

Phase: N/A Priority: Normal
NCT ID: NCT00117650 Org: User:
Start: 02/28/05 End: 03/31/10 Due: 03/31/11

A Study of Fabrazyme in Pediatric Patients With Fabry Disease

Phase: N/A Priority: Normal
NCT ID: NCT00074958 Org: User:
Start: 10/31/02 End: 07/31/05 Due: 07/31/06

ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial

Phase: N/A Priority: Normal
NCT ID: NCT00752986 Org: User:
Start: 12/31/08 End: 09/30/13 Due: 09/30/14

Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)

Phase: N/A Priority: Normal
NCT ID: NCT00206726 Org: User:
Start: 05/31/05 End: 04/30/08 Due: 04/30/09